Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

Authors: Jazieh, Khalid, Babiker, Hani M., Foster, Nathan R., Fruth, Briant, Carr, Ryan Michael, Alberts, Steven R, Conboy, Caitlin, Tran, Nguyen H., Hartgers, Mindy L., Halfdanarson, Thorvardur Ragnar, Starr, Jason S., Sonbol, Mohamad Bassam, Jones, Jeremy Clifton, Ahn, Daniel H., Kankeu Fonkoua, Lionel Aurelien, Wu, Christina, Pedersen, Katrina Sophia, Bekaii-Saab, Tanios S., McWilliams, Robert R.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p727-727, 121p

Interim safety and efficacy data of [ 212 Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs).

Authors: Wahl, Richard L., Anthony, Lowell Brian, Solnes, Lilja B., Mehr, Samuel H., Baratto, Lucia, Hanna, Alaa, Yang, Wenjing M., Keefe, Stephen Michael, Halfdanarson, Thorvardur Ragnar

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p668-668, 20p

Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).

Authors: Strosberg, Jonathan R., Zemla, Tyler J., Geyer, Susan Michelle, Knopp, Michael V., Behr, Spencer, Pulsipher, Sydney, Acoba, Jared David, Shergill, Ardaman, Wolin, Edward M., Halfdanarson, Thorvardur Ragnar, Konda, Bhavana, Trikalinos, Nikolaos, Tawfik, Bernard, Raj, Nitya Prabhakar, Shaheen, Shagufta, Vijayvergia, Namrata, Dasari, Arvind, O'Reilly, Eileen M., Meyerhardt, Jeffrey A., Chan, Jennifer A.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p666-666, 20p

Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents.

Authors: Strosberg, Jonathan R., Koumarianou, Anna, Riechelmann, Rachel, Hernando, Jorge, Cingarlini, Sara, Crona, Joakim, Al-Toubah, Taymeyah E., Apostolidis, Leonidas, Bergsland, Emily K., Halfdanarson, Thorvardur Ragnar, Cros, Jerome, De Mestier DU Bourg, Louis

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p662-662, 20p

First line atezolizumab + bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.

Authors: Kournoutas, Ioannis, Marell, Paulina S, Peersen, Anina, Gupta, Garima, Akce, Mehmet, Yang, Ju Dong, Chen, Pin-Jung, Naleid, Nikolas, Mahipal, Amit, Sahai, Vaibhav, Thompson, Scott, Jin, Zhaohui, Venkatesh, Sudhakar, Borad, Mitesh J., Babiker, Hani M., Bekaii-Saab, Tanios S., McWilliams, Robert R., Halfdanarson, Thorvardur Ragnar, Ou, Fang-Shu, Tran, Nguyen H.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p532-532, 132p

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Authors: Duma, Narjust, Kothadia, Sejal M., Azam, Tariq U., Yadav, Siddhartha, Paludo, Jonas, Vera Aguilera, Jesus, Gonzalez Velez, Miguel, Halfdanarson, Thorvardur Ragnar, Molina, Julian R., Hubbard, Joleen M., Go, Ronald S., Mansfield, Aaron S., Adjei, Alex A.

Source: Oncologist. 24(1):96-102

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100082764972.0x000001&indx=1&recIds=ETOCvdc_100082764972.0x000001

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.

Authors: McGarrah, Patrick Walsh, Naik, Shruthi, Halfdanarson, Thorvardur Ragnar, Peng, Kah Whye, Russell, Stephen J., Molina, Julian R., Adjei, Alex A.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS602-TPS602, 15p

[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Authors: Singh, Simron, Halperin, Daniel M., Myrehaug, Sten, Herrmann, Ken, Pavel, Marianne, Kunz, Pamela L., Chasen, Beth, Capdevila, Jaume, Tafuto, Salvatore, Oh, Do-Youn, Yoo, Changhoon, Falk, Stephen, Halfdanarson, Thorvardur Ragnar, Folitar, Ilya, Zhang, Yufen, Santoro, Paola, Aimone, Paola, de Herder, Wouter W., Ferone, Diego

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pLBA588-LBA588, 6p

Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma.

Authors: Eslinger, Cody, Yee, Claire, Seddighzadeh, Bobak, Elsabbagh, Zaid, Pai, Rish, Hartley, Christopher P., Bekaii-Saab, Tanios S., Starr, Jason S., Halfdanarson, Thorvardur Ragnar, Sonbol, Bassam Bassam

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p688-688, 117p

Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.

Authors: Mosalem, Osama M, Coston, Tucker, Pai, Tanmayi, Sonbol, Bassam Bassam, Parent, Ephraim E., Young, Jason R., Johnson, Geoffrey, Kendi, Ayse T., Halfdanarson, Thorvardur Ragnar, Starr, Jason S.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p592-592, 15p

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.

Authors: Saberzadeh Ardestani, Bahar, Jones, Jeremy Clifton, McWilliams, Robert R., Tougeron, David, Halfdanarson, Thorvardur Ragnar, Guimbaud, Rosine, Hubbard, Joleen M., Flecchia, Clémence, Shi, Qian, Alouani, Emily Linda, Sonbol, Bassam Bassam, Ticku, Jonathan, Jin, Zhaohui, Taieb, Julien, Sinicrope, Frank A.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p55-55, 235p

Disparities in overall survival (OS) outcomes based on treating facility volume in pancreatic neuroendocrine tumors.

Authors: Tella, Sri Harsha, Kommalapati, Anuhya, Desai, Aakash, McGarrah, Patrick Walsh, Hobday, Timothy J., Halfdanarson, Thorvardur Ragnar

Source: Journal of clinical oncology. 40(28 suppl):150-150

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100179130336.0x000001&indx=1&recIds=ETOCvdc_100179130336.0x000001

Clinical outcomes of neoadjuvant treatment strategies in localized mismatch repair-deficient rectal cancer.

Authors: Soderberg, Leah C, Wookey, Vanessa, Mitchell, Jessica L., Jochum, Jacob A., Tran, Nguyen H., Halfdanarson, Thorvardur Ragnar, Hubbard, Joleen M., Graham, Rondell P., Mathis, Kellie Leanne, Mahipal, Amit, Jin, Zhaohui

Source: Journal of clinical oncology. 40(4 suppl):192-192

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155645375.0x000001&indx=1&recIds=ETOCvdc_100155645375.0x000001

A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.

Authors: Ma, Wen Wee, Zemla, Tyler J., Walden, Daniel, McWilliams, Robert R., Shaib, Walid Labib, Ahn, Daniel H., El-Rayes, Bassel F., Halfdanarson, Thorvardur Ragnar, Hobday, Timothy J., Bruggeman, Sarah, Jaszewski, Brandy L., Ou, Fang-Shu, Wu, Christina, Bekaii-Saab, Tanios S.

Source: Journal of clinical oncology. 40(4 suppl):563-563

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152970288.0x000001&indx=1&recIds=ETOCvdc_100152970288.0x000001

Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Authors: Halfdanarson, Thorvardur Ragnar, Reidy, Diane Lauren, Vijayvergia, Namrata, Halperin, Daniel M., Goldstein, Grace, Kong, Grace, Michael, Michael, Leyden, Simone, Grozinsky-Glasberg, Simona, Sorbye, Halfdan, Oberg, Kjell E., Sierras, Cristina, Harris, Philip

Source: Journal of clinical oncology. 40(4 suppl):TPS514-TPS514

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152968448.0x000001&indx=1&recIds=ETOCvdc_100152968448.0x000001

Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.

Authors: McGarrah, Patrick Walsh, Gile, Jennifer, Liu, Alex John, Mansfield, Aaron Scott, Leventakos, Konstantinos, Desai, Aakash, Tella, Sri Harsha, Sonbol, Bassam Bassam, Starr, Jason S., Hobday, Timothy J., Halfdanarson, Thorvardur Ragnar

Source: Journal of clinical oncology. 40(4 suppl):512-512

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152968365.0x000001&indx=1&recIds=ETOCvdc_100152968365.0x000001

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC).

Authors: Hickman, Ashley Deanelle, McGarrah, Patrick Walsh, Glaser, Gretchen, Naraev, Boris, Wahner Hendrickson, Andrea Elisabeth, Halfdanarson, Thorvardur Ragnar

Source: Journal of clinical oncology. 39(15 suppl):e17518-e17518

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173207695.0x000001&indx=1&recIds=ETOCvdc_100173207695.0x000001

INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients.

Authors: Spada, Francesca, Gervaso, Lorenzo, La Salvia, Anna, Garcia-Carbonero, Rocio, Hernando, Jorge, Capdevila, Jaume, Hofland, Johannes, de Herder, Wouter, Koumarianou, Anna, Rossi, Maura, Boselli, Sabrina, Tamayo, Darina, Bagnardi, Vincenzo, Laffi, Alice, Rubino, Manila, Sonbol, Mohamad Bassam, Fazio, Nicola, Halfdanarson, Thorvardur Ragnar

Source: Journal of clinical oncology. 39(15 suppl):e16205-e16205

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173200920.0x000001&indx=1&recIds=ETOCvdc_100173200920.0x000001

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.

Authors: Wagner, Michael J, Ingham, Matthew, Painter, Corrie, Chugh, Rashmi, Trent, Jonathan C., Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa May Ling, Loggers, Elizabeth Trice, Labaki, Chris, McKay, Rana R., Griffiths, Elizabeth A., Thornton, Katherine Anne, Kasi, Anup, Hwang, Clara, Chen, James Lin, Halfdanarson, Thorvardur Ragnar, Reuben, Daniel Y., Park, Cathleen, Davis, Elizabeth J.

Source: Journal of clinical oncology. 39(15 suppl):11523-11523

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173105998.0x000001&indx=1&recIds=ETOCvdc_100173105998.0x000001

This result is not displayed to guests.
Login for full access.